Entering text into the input field will update the search result below

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q4 2019 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2019 Results Earnings Conference Call March 9, 2020 8:00 AM ET

Company Participants

Peter Vozzo - Investor Relations

Jerry Jabbour - Chief Executive Officer

Terry Ferguson - Chief Medical Officer

Terry Matkovits - Chief Development Officer

Keith Kucinski - Chief Financial Officer.

Conference Call Participants

Robert Hazlett - BTIG

Edward Tenthoff - Piper Sandler

Greg Fraser - SunTrust

Jason McCarthy - Maxim Group


Greetings, and welcome to the Matinas BioPharma Fourth Quarter and Full Year 2019 Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.

I would now like to turn the conference over to Peter Vozzo, Investor Relations representative from Matinas BioPharma. You may begin.

Peter Vozzo

Thank you, Rob. Good morning, everyone and thank you for joining the Matinas BioPharma fourth quarter and full year 2019 results conference call. Earlier this morning, we issued a press release with our fourth quarter and full year 2019 financial results along with business updates. The release is available on the Matinas BioPharma website under the Investors section.

Speaking on today's call will be Jerry Jabbour, Chief Executive Officer, Dr. Terry Ferguson, Chief Medical Officer, Dr. Terry Matkovits, Chief Development Officer and Keith Kucinski, Chief Financial Officer.

At this time, I would like to remind our listeners that remarks made during this call may state management's intentions, hopes, beliefs, expectations or projections of the future. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the Safe Harbor provisions of the Federal Securities Laws. These forward-looking statements are based on Matinas BioPharma's current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.